Krystal Biotech Epidermolysis Bullosa Study Data Published In New England Journal Of Medicine

Krystal Biotech Inc KRYS announced that data from the pivotal Phase 3 (GEM-3) trial of beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa (DEB) had been published in the New England Journal of Medicine (NEJM).
The 31-patient study showed complete wound healing at six months occurred in 67.4% of B-VEC wounds compared to 21.6% for placebo.
Related: Krystal Biotech's Subsidiary Posts Durability Data For Fine Line, Wrinkles.
Complete wound healing at three months occurred in 70.6% of the wounds exposed to B-VEC compared to 19.7% of those exposed to placebo.
The FDA accepted the marketing application for B-VEC under the Priority Review designation, and the Prescription Drug User Fee Act action date is February 17, 2023.
Price Action: KRYS shares closed at $77.65 on Wednesday.

Momentum19.30

GrowthNot Available

QualityNot Available

Value47.14

Short

Medium

Long